Estimation of MRSA Susceptibility to Oxacillin, Cefoxitine, Vancomycin and Daptomyci

Prevalence and therapy of infections due to MRSA remain one of the most serious problems in the world. Therefore, correct laboratory identification of the MRSA phenotype based on the use of the marker antibiotic cefoxitine, as a more susceptibile one vs. oxacillin, is of great importance. There is lately being observed a tendency towards emergence of strains with lower susceptibility to the last reserve drugs protecting from MRSA, i. e. vancomycin amd daptomycin. Susceptibility of MSRA to these drugs was not investigated in Russia and there are no data on the prevalence of the VISA and hVISA phenotypes. The results of our study on estimation of susceptibility of 316 MRSA isolates from several regions of Russia to oxacillin, cefoxitine, vancomycin and daptomycin are presented herein. It was shown that the ranges of the oxacillin MIC were extremely wide, i. e. 0.5 to 512 mcg/ml, while 2.2±1% of the isolates was susceptible by the phenotype to oxacillin, in spite of the mecA gene presence. As for cefoxitine, the MRSA isolates were rather resistant to it at the MIC > 16 mcg/ml. The tests with serial microdilutions revealed that 30.7±7% of the isolates had a critical level of susceptibility to vancomycin at the MIC 2 mcg/ml. The E-tests revealed 1.3±1% of the isolates which were susceptible at the MIC 2-4 mcg/ml. The MRSA isolates were highly susceptible to daptomycin, while high levels of the MIC (2 mcg/ml) were characteristic of 2.8±1% of the isolates. Cross reduction of the susceptibility to vancomycin and daptomycin was observed.

methicillin resistant staphylococci (MRSA), oxacillin, cefoxitine, vancomycin, daptomycin

1. Chambers H.F. Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin Microbiol Rev 1997; 10: 4: 781-791.

2. Ikonomidis A., Michail G., Vasdeki A., Labrou M., Karavasilis V., Stathopoulos C., Maniatis A.N., Pournaras S. In vitro and in vivo evaluations of oxacillin efficiency against mecA-positive oxacillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2008, 52: 11: 3905-3908.

3. Perichon B., Courvalin P. VanA-type vancomycin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009, 53: 11: 4580-4587.

4. Howden B.P., Davies J.K., Johnson P.D., Stinear T.P., Grayson M.L. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010: 23: 1: 99-139.

5. Walsh T.R., Bolmstrom A., Qwarnstrom A., Ho P., Wootton M., Howe R.A., MacGowan A.P., Diekema D. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 2001; 39: 7: 2439-2444.

6. Musta A.C., Riederer K., Shemes S., Chase P., Jose J., Johnson L.B., Khatib R. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol 2009; 47: 6: 1640-1644.

7. Wi Y.M., Kim J.M., Joo E.J., Ha Y.E., Kang C.I., Ko K.S., Chung D.R., Song J.H., Peck K.R. High vancomycin minimum inhibitory concentration is a predictor of mortality in methicillin-resistant Staphylococcus aureus bacteraemia. Int J Antimicrob Agents 2012; 40: 2: 108-113.

8. Steenbergen J.N., Alder J., Thorne G.M., Tally F.P. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 2005; 55: 3: 283-288.

9. Kelley P.G., Gao W., Ward P.B., Howden B.P. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. J Antimicrob Chemother 2011; 66: 5: 1057- 1060.

10. Гланц С. Медико-биологическая статистика. М.: 1999.

11. Figueiredo A.M., Ha E., Kreiswirth B.N., de Lencastre H., Noel G.J., Senterfit L., Tomasz A. In vivo stability of heterogeneous expression classes in clinical isolates of methicillin-resistant staphylococci. J Infect Dis 1991; 164: 5: 883-887.

12. Tomasz A., Nachman S., Leaf H. Stable classes of phenotypic expression in methicillin-resistant clinical isolates of staphylococci. Antimicrob Agents Chemother 1991; 35: 1: 124-129.

13. Гостев B.B., Сидоренко С.В. Тип стафилококковой хромосомной mec-кассеты (SCCmec) и уровень резистентности метициллинрезистентных Staphylococcus aureus к оксациллину. Проблем. мед. микол. 2012; 14: 2: 77-78.

14. Saeed K., Dryden M., Parnaby R. Oxacillin-susceptible MRSA, the emerging MRSA clone in the UK? J Hosp Infect 2010; 76: 3: 267-268.

15. Sakoulas G., Gold H.S., Venkataraman L., DeGirolami P.C., Eliopoulos G.M., Qian Q. Methicillin-resistant Staphylococcus aureus: comparison of susceptibility testing methods and analysis of mecA-positive susceptible strains. J Clin Microbiol 2001; 39: 11: 3946-3951.

16. Nadarajah R., Post L.R., Liu C., Miller S.A., Sahm D.F., Brooks G.F. Detection of vancomycin-intermediate Staphylococcus aureus with the updated Trek-Sensititre System and the MicroScan System. Comparison with results from the conventional Etest and CLSI standardized MIC methods. Am J Clin Pathol 2010; 133: 6: 844-848.

17. Satola S.W., Farley M.M., Anderson K.F., Patel J.B. Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method. J Clin Microbiol 2011; 49: 1: 177-183.

18. Pitz A.M., Yu F., Hermsen E.D., Rupp M.E., Fey P.D., Olsen K.M. Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S.aureus isolates. J Clin Microbiol 2011; 49: 1: 269-274.

19. Holmes R.L., Jorgensen J.H. Inhibitory activities of 11 antimicrobial agents and bactericidal activities of vancomycin and daptomycin against invasive methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006. Antimicrob Agents Chemother 2008, 52: 2: 757-760.

20. Adam H.J., Louie L., Watt C., Gravel D., Bryce E., Loeb M., Matlow A., McGeer A., Mulvey M.R., Simor A.E. Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006. Antimicrob Agents Chemother 2010; 54: 2: 945-949.

21. Khosrovaneh A., Riederer K., Saeed S., Tabriz M.S., Shah A.R., Hanna M.M., Sharma M., Johnson L.B., Fakih M.G., Khatib R. Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2004; 38: 9: 1328-1330.

22. Wootton M., MacGowan A.P., Walsh T.R., Howe R.A. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J Clin Microbiol 2007; 45: 2: 329-332.

23. Critchley I.A., Draghi D.C., Sahm D.F., Thornsberry C., Jones M.E., Karlowsky J.A. Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001. J Antimicrob Chemother 2003; 51: 3: 639-649.

24. Sader H.S., Fey P.D., Limaye A.P., Madinger N., Pankey G., Rahal J., Rybak M.J., Snydman D.R., Steed L.L., Waites K. et al. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob Agents Chemother 2009; 53: 10: 4127-4132.

25. Sader H.S., Rhomberg P.R., Jones R.N. Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and dap-tomycin against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009; 53: 7: 3162-3165.

26. Streit J.M., Jones R.N., Sader H.S. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. J Antimicrob Chemother 2004; 53: 4: 669-674.

27. van Hal S.J., Paterson D.L., Gosbell I.B. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naive patient - a review of the literature. Eur J Clin Microbiol Infect Dis 2011; 30: 5: 603-610.

28. Kirby A., Edwards C., Broughton C.M., Williams N.J. Glycopeptide and daptomycin resistance in community-associated MRSA in the UK. Infection 2011; 39: 3: 277-279.

29. Skiest D.J. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 2006; 44: 2: 655-656.

30. Fischer A., Yang S.J., Bayer A.S., Vaezzadeh A.R., Herzig S., Stenz L., Girard M., Sakoulas G., Scherl A., Yeaman M.R. et al. Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach. J Antimicrob Chemother 2011; 66: 8: 1696-1711.

31. Peleg A.Y., Miyakis S., Ward D.V., Earl A.M., Rubio A., Cameron D.R., Pillai S., Moellering R.C., Eliopoulos G.M. Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus. PLoS One 2012; 7: 1: e28316.